Literature DB >> 2857365

Serum inhibitory factors (SIF) are of prognostic value in acute viral hepatitis.

K H Wiedmann, N W Brattig, G D Diao, H Schomerus, W Dölle, P A Berg.   

Abstract

Serum inhibitory factors (SIF) were analysed in relation to the natural course of acute viral hepatitis in 81 patients followed over a period of 1 year. 63 patients recovered completely (group 1), and 18 had a protracted course of hepatitis (group 2) as shown by persistent transaminase activity 6 months after onset. 11 patients in group 2 still had signs of liver disease after 1 year. A gradual fall of SIF activity (in 47 patients) heralded resolving hepatitis, whereas persistence of SIF (in 8 patients) correlated with inflammatory activity and failure of hepatitis B viral antigen elimination. Absence of SIF activity was associated with either an uncomplicated or a chronic course of hepatitis in 23 and 3 patients, respectively. Repeated determination of SIF may help to predict the final outcome of hepatitis. Both excessive and failure of SIF production may result in the development of chronic liver disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857365     DOI: 10.1016/s0140-6736(85)91083-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Serum immunomodulatory factors in gastrointestinal diseases. A 30-50-kD serum fraction in Crohn's disease capable of modulating lymphocyte activation.

Authors:  L Biancone; M Boirivant; S Fais; G L Ricci; R Paganelli; F Pallone
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  How often does chronic liver disease follow acute hepatitis B in adults?

Authors:  A Roumeliotou-Karayannis; N Tassopoulos; S C Richardson; P Kalafatas; G Papaevangelou
Journal:  Infection       Date:  1985 Jul-Aug       Impact factor: 3.553

3.  Clinical outcome of a patient cohort with acute hepatitis B.

Authors:  Laura Alves de Souza; Angelo Alves de Mattos; Maristela Fiorini; Polyanna Ribeiro; Cristiane Valle Tovo
Journal:  Clinics (Sao Paulo)       Date:  2013-05       Impact factor: 2.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.